Novel Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation: Dawn of a New Era

References

• . Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995;155(5):469–473
   PubMedGoogle Scholar
• . Go AS, Hylek EM, Phillips KA, . Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–2375
   PubMed Web of Science ®Google Scholar
• . Miyasaka Y, Barnes ME, Gersh BJ, . Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–125
   PubMed Web of Science ®Google Scholar
• . Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–272
   PubMed Web of Science ®Google Scholar
• . Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–2870
   PubMed Web of Science ®Google Scholar
• . Harrison M, Marshall J. Atrial fibrillation, TIAs and completed strokes. Stroke. 1984;15(3):441–442
   PubMedGoogle Scholar
• . Hart RG, Pearce LAAguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867
   PubMed Web of Science ®Google Scholar
• . Weitz JI. Hemostasis, thrombosis, fibrinolysis, and cardiovascular disease. In: Zipes, DP, Libby P, Bonow RO, Braunwald E, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Single volume, 7th ed: Saunders; 2004:1861–1863
   Google Scholar
• . Connolly SJ, Pogue J, Eikelboom J, ; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118(20):2029–2037
   PubMed Web of Science ®Google Scholar
• . Singer DE, Albers GW, Dalen JE, ; American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133( 6 suppl):546S–592S
   Google Scholar
• . Crowther MA, Ageno W, Garcia D, . Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med. 2009;150(5):293–300
   PubMed Web of Science ®Google Scholar
• . Francis CW, Berkowitz SD, Comp PC, ; EXULTA Study Group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003;349(18):1703–1712
   PubMed Web of Science ®Google Scholar
• . Olsson SB; Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362(9397):1691–1698
   PubMed Web of Science ®Google Scholar
• . Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol. 2010;196:407–418
   PubMedGoogle Scholar
• . Blech S, Ebner T, Ludwig—Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36(2):386–399
   PubMed Web of Science ®Google Scholar
• . Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47(5):285–295
   PubMed Web of Science ®Google Scholar
• . Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2012. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf). Accessed November 6, 2011
   Google Scholar
• . Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract. 2010;64(7):956–967
   PubMed Web of Science ®Google Scholar
• . van Ryn J, Stangier J, Haertter S, . Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116–1127
   PubMed Web of Science ®Google Scholar
• . Connolly SJ, Ezekowitz MD, Yusuf S, ; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151
   PubMed Web of Science ®Google Scholar
• . Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363(19):1875–1876
   PubMed Web of Science ®Google Scholar
• . Hohnloser SH, Oldgren J, Yang S, . Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012;125(5):669–676
   PubMed Web of Science ®Google Scholar
• . Lawson JH, Murphy MP. Challenges for providing effective hemostasis in surgery and trauma. Semin Hematol. 2004;41(1 suppl 1):55–64
   PubMedGoogle Scholar
• . Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59–7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78(4):412–421
   PubMed Web of Science ®Google Scholar
• . Xareltotablets [package insert]. Titusville, NJ: Jannsen Pharmaceuticals, Inc.; 2012. http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf#zoom=100. Accessed December 28, 2012
   Google Scholar
• . Patel MR, Mahaffey KW, Garg J, ; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891
   PubMed Web of Science ®Google Scholar
• . Johnson & Johnson Pharmaceutical Research and Development. Advisory Briefing Document. Rivaroxaban for the prevention of stroke and non-central nervous system (CNS) systemic embolism in patients with atrial fibrillation. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrug-sAdvisoryCommittee/UCM270797.pdf. Published August 5, 2011. Accessed December 28, 2012
   Google Scholar
• . Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011;50(10):675–686
   PubMed Web of Science ®Google Scholar
• . Granger CB, Alexander JH, McMurray JJ, ; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial Fibrillation. N Engl J Med. 2011;365(11):981–992
   PubMed Web of Science ®Google Scholar
• . Connolly SJ, Eikelboom J, Joyner C, ; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–817
   PubMed Web of Science ®Google Scholar
• . Ogata K, Mendell—Harary J, Tachibana M, . Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50(7):743–753
   PubMed Web of Science ®Google Scholar
• . Weitz JI, Connolly SJ, Patel I, . Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104(3):633–641
   PubMed Web of Science ®Google Scholar
• . Ruff CT, Giugliano RP, Antman EM, . Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160(4):635–641
   PubMed Web of Science ®Google Scholar
• . Boehringer Ingelheim Pharmaceuticals, Inc. Advisory committee briefing document [dabigatran etexilate]. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascu-larandrenaldrugsadvisorycommittee/ucm226009.pdf Published August 27, 2010. Accessed December 28, 2012
   Google Scholar
• . Wallentin L, Yusuf S, Ezekowitz MD, ; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975–983
   PubMed Web of Science ®Google Scholar
• . Camm AJ, Lip GY, De Caterina R, ; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–2747
   PubMed Web of Science ®Google Scholar
• . Schulman S, Eriksson H, Goldhaber SZ, . Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. Presented at: International Society on Thrombosis and Haemostasis; July 28, 2011;Kyoto, Japan. Abstract O-TH-033
   Google Scholar
• . Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172(5):397–402
   PubMed Web of Science ®Google Scholar
• . Bauer KA. Reversal of antithrombotic agents. Am J Hematol. 2012;87( suppl 1):S119–S126
   Web of Science ®Google Scholar
• . Pragst I, Zeitler SH, Doerr B, . Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost. 2012;10(9):1841–1848
   PubMed Web of Science ®Google Scholar
• . Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HRLevi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573–1579
   PubMed Web of Science ®Google Scholar
• . Fukuda T, Honda Y, Kamisato C, Morishima Y, Shibano T. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost. 2012;107(2):253–259
   PubMed Web of Science ®Google Scholar
• . Samama CM. Prothrombin complex concentrates: a brief review. Eur J Anaesthesiol. 2008;25(10):784–789
   PubMed Web of Science ®Google Scholar
• . Wartak SA, Bartholomew JR. Dabigatran: will it change clinical practice? Cleve Clin J Med. 2011;78(10):657–664
   PubMedGoogle Scholar
• . You JJ, Singer DE, Howard PA, ; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141( 2 suppl):e531S–e575S
   PubMed Web of Science ®Google Scholar
• . Fuster V, Rydén LE, Asinger RW, ; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation); North American Society of Pacing and Electrophysiology ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation. 2001;104(17):2118–2150
   PubMed Web of Science ®Google Scholar
• . Nagarakanti R, Ezekowitz MD, Oldgren J, . Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123(2):131–136
   PubMed Web of Science ®Google Scholar
• . Lakkireddy D, Reddy YM, Di Biase L, . Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2012;59(13):1168–1174
   PubMed Web of Science ®Google Scholar
• . Eitel C, Hindricks G, Piorkowski C. Dabigatran in patients post atrial fibrillation ablation. J Am Coll Cardiol. 2012;59(13 s1):E603–E603
   Google Scholar
• . van Walraven C, Hart RG, Singer DE, . Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288(19):2441–2448
   PubMed Web of Science ®Google Scholar
• . Skanes AC, Healey JS, Cairns JA, ; Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol. 2012;28(2):125–136
   PubMed Web of Science ®Google Scholar